Quick Answer
INOVIO PHARMACEUTICALS, INC. reported Stockholders Equity of $24.10 million for the year ending 2025.
- INOVIO PHARMACEUTICALS, INC. showed a decrease of -64.8% in Stockholders Equity from 2024 to 2025.
- This data is from INOVIO PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $55.01 million | Q3 2011: $50.75 million | Q1 2012: $39.69 million | Q2 2012: $35.83 million | Q3 2012: $30.76 million | Q1 2013: $39.93 million | Q2 2013: $29.20 million | Q3 2013: $61.76 million | Q1 2014: $128.74 million | Q2 2014: $121.84 million | Q3 2014: $116.73 million | Q1 2015: $103.12 million | Q2 2015: $180.56 million | Q3 2015: $193.14 million | Q1 2016: $170.97 million | Q2 2016: $161.99 million | Q3 2016: $146.88 million | Q1 2017: $105.85 million | Q2 2017: $123.43 million | Q3 2017: $162.02 million | Q1 2018: $113.00 million | Q2 2018: $111.40 million | Q3 2018: $103.61 million | Q1 2019: $77.91 million | Q2 2019: $53.62 million | Q3 2019: $33.69 million | Q1 2020: $184.32 million | Q2 2020: $186.26 million | Q3 2020: $323.90 million | Q1 2021: $581.61 million | Q2 2021: $508.55 million | Q3 2021: $453.57 million | Q1 2022: $355.09 million | Q2 2022: $297.67 million | Q3 2022: $266.70 million | Q1 2023: $199.21 million | Q2 2023: $169.37 million | Q3 2023: $138.16 million | Q1 2024: $94.44 million | Q2 2024: $96.74 million | Q3 2024: $73.54 million | Q1 2025: $51.25 million | Q2 2025: $28.53 million | Q3 2025: -$7.72 million.
- Over the full 16 years of available data (2010 to 2025), INOVIO PHARMACEUTICALS, INC.'s Stockholders Equity has declined by 48.2%.
- Historical annual values: Fiscal year 2025: $24.10 million | Fiscal year 2024: $68.50 million | Fiscal year 2023: $117.35 million | Fiscal year 2022: $222.36 million | Fiscal year 2021: $399.67 million | Fiscal year 2020: $461.14 million | Fiscal year 2019: $3.44 million | Fiscal year 2018: $86.94 million | Fiscal year 2017: $142.39 million | Fiscal year 2016: $123.28 million | Fiscal year 2015: $175.69 million | Fiscal year 2014: $111.23 million | Fiscal year 2013: $52.46 million | Fiscal year 2012: $34.35 million | Fiscal year 2011: $47.31 million | Fiscal year 2010: $46.50 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: